- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02257528
Nivolumab bei der Behandlung von Patienten mit persistierendem, rezidivierendem oder metastasiertem Gebärmutterhalskrebs
Eine Phase-II-Evaluierung von Nivolumab, einem vollständig menschlichen Antikörper gegen PD-1, bei der Behandlung von persistierendem oder rezidivierendem Gebärmutterhalskrebs
This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To assess the antitumor activity (proportion of objective response by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) of nivolumab with objective tumor response in patients with persistent, recurrent or metastatic carcinoma of the cervix.
II. To determine the nature and degree of toxicity of nivolumab as assessed by Common Terminology Criteria for Adverse Events (CTCAE) in patients with persistent, recurrent or metastatic carcinoma of the cervix.
SECONDARY OBJECTIVES:
I. To estimate the duration of progression-free survival (PFS) and overall survival (OS).
TERTIARY OBJECTIVES:
I. To systematically evaluate programmed cell death (PD)-1 and B7 homolog 1 (B7-H1) (i.e., PD-1 ligand) expression in tumor infiltrating lymphocytes (TILs) and cervical cancer cells and explore their correlations with objective response, PFS, and OS in nivolumab-treated patients with PD-1 and B7-H1 scoring results.
II. To explore the composition of immune infiltrates in tumor specimens/biopsies from primary and/or metastatic/recurrent sites with selected markers including (but not limited) to cluster of differentiation (CD)4+, CD8+, forkhead box P3 (FoxP3), CD25, lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin mucin-3 (TIM-3), and inducible T-cell co-stimulator (ICOS) and their correlations to objective response, PFS and OS in nivolumab-treated patients.
III. To evaluate human papillomavirus (HPV) status and to explore the changes of pre- and post-immune therapy responses to HPV16/18/31/35/45 E7 antigens in patients peripheral blood lymphocytes (PBL) and serum using proliferative and interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) (cellular immunity) and serological (enzyme-linked immunosorbent assay [ELISA]) assays.
IV. To explore the levels of circulating tumor cells (CTCs) pre-treatment and at 8 and 12 weeks and their association with patient outcome.
OUTLINE:
Patients receive nivolumab intravenously (IV) over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Alaska
-
Anchorage, Alaska, Vereinigte Staaten, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Vereinigte Staaten, 99504
- Anchorage Radiation Therapy Center
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Alaska Regional Hospital
-
-
Arkansas
-
Hot Springs, Arkansas, Vereinigte Staaten, 71913
- CHI Saint Vincent Cancer Center Hot Springs
-
-
California
-
Auburn, California, Vereinigte Staaten, 95602
- Sutter Auburn Faith Hospital
-
Auburn, California, Vereinigte Staaten, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Baldwin Park, California, Vereinigte Staaten, 91706
- Kaiser Permanente-Baldwin Park
-
Berkeley, California, Vereinigte Staaten, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Burbank, California, Vereinigte Staaten, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Burlingame, California, Vereinigte Staaten, 94010
- Mills-Peninsula Medical Center
-
Cameron Park, California, Vereinigte Staaten, 95682
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park
-
Castro Valley, California, Vereinigte Staaten, 94546
- Eden Hospital Medical Center
-
Davis, California, Vereinigte Staaten, 95616
- Sutter Davis Hospital
-
La Jolla, California, Vereinigte Staaten, 92093
- UC San Diego Moores Cancer Center
-
Modesto, California, Vereinigte Staaten, 95355
- Memorial Medical Center
-
Mountain View, California, Vereinigte Staaten, 94040
- Palo Alto Medical Foundation-Camino Division
-
Mountain View, California, Vereinigte Staaten, 94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
Palo Alto, California, Vereinigte Staaten, 94301
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Vereinigte Staaten, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville, California, Vereinigte Staaten, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Vereinigte Staaten, 95816
- Sutter Medical Center Sacramento
-
San Diego, California, Vereinigte Staaten, 92120
- Kaiser Permanente-San Diego Zion
-
San Diego, California, Vereinigte Staaten, 92108
- Kaiser Permanente-Rio San Diego
-
San Francisco, California, Vereinigte Staaten, 94115
- California Pacific Medical Center-Pacific Campus
-
San Marcos, California, Vereinigte Staaten, 92078
- Kaiser Permanente-San Marcos
-
Santa Cruz, California, Vereinigte Staaten, 95065
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Vereinigte Staaten, 95403
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Vereinigte Staaten, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Vereinigte Staaten, 94589
- Sutter Solano Medical Center/Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06520
- Yale University
-
-
Delaware
-
Lewes, Delaware, Vereinigte Staaten, 19958
- Beebe Medical Center
-
Newark, Delaware, Vereinigte Staaten, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Vereinigte Staaten, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Vereinigte Staaten, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Vereinigte Staaten, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Vereinigte Staaten, 19971
- Beebe Health Campus
-
Seaford, Delaware, Vereinigte Staaten, 19973
- TidalHealth Nanticoke / Allen Cancer Center
-
Wilmington, Delaware, Vereinigte Staaten, 19801
- Christiana Care Health System-Wilmington Hospital
-
-
Georgia
-
Savannah, Georgia, Vereinigte Staaten, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Vereinigte Staaten, 31404
- Memorial Health University Medical Center
-
Savannah, Georgia, Vereinigte Staaten, 31404
- Summit Cancer Care-Memorial
-
Savannah, Georgia, Vereinigte Staaten, 31404
- Low Country Cancer Care
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83712
- Saint Luke's Cancer Institute - Boise
-
Coeur d'Alene, Idaho, Vereinigte Staaten, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Vereinigte Staaten, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Vereinigte Staaten, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Vereinigte Staaten, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Vereinigte Staaten, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Vereinigte Staaten, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Vereinigte Staaten, 61704
- Illinois CancerCare-Bloomington
-
Bloomington, Illinois, Vereinigte Staaten, 61701
- OSF Saint Joseph Medical Center
-
Canton, Illinois, Vereinigte Staaten, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Vereinigte Staaten, 62902
- Memorial Hospital of Carbondale
-
Carthage, Illinois, Vereinigte Staaten, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Vereinigte Staaten, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Northwestern University
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Crossroads Cancer Center
-
Eureka, Illinois, Vereinigte Staaten, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Vereinigte Staaten, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Vereinigte Staaten, 61401
- Illinois CancerCare-Galesburg
-
Hinsdale, Illinois, Vereinigte Staaten, 60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
Kewanee, Illinois, Vereinigte Staaten, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Vereinigte Staaten, 61455
- Illinois CancerCare-Macomb
-
Mount Vernon, Illinois, Vereinigte Staaten, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Vereinigte Staaten, 61350
- Illinois CancerCare-Ottawa Clinic
-
Ottawa, Illinois, Vereinigte Staaten, 61350
- Radiation Oncology of Northern Illinois
-
Pekin, Illinois, Vereinigte Staaten, 61554
- Illinois CancerCare-Pekin
-
Pekin, Illinois, Vereinigte Staaten, 61554
- OSF Saint Francis Radiation Oncology at Pekin
-
Peoria, Illinois, Vereinigte Staaten, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Vereinigte Staaten, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Vereinigte Staaten, 61615
- Illinois CancerCare-Peoria
-
Peoria, Illinois, Vereinigte Staaten, 61615
- OSF Saint Francis Radiation Oncology at Peoria Cancer Center
-
Peru, Illinois, Vereinigte Staaten, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Vereinigte Staaten, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, Vereinigte Staaten, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Springfield Clinic
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Central Illinois Hematology Oncology Center
-
Springfield, Illinois, Vereinigte Staaten, 62781
- Springfield Memorial Hospital
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Sidney and Lois Eskenazi Hospital
-
Richmond, Indiana, Vereinigte Staaten, 47374
- Reid Health
-
-
Iowa
-
Clive, Iowa, Vereinigte Staaten, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Vereinigte Staaten, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Vereinigte Staaten, 51503
- Alegent Health Mercy Hospital
-
Creston, Iowa, Vereinigte Staaten, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Vereinigte Staaten, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Chanute, Kansas, Vereinigte Staaten, 66720
- Cancer Center of Kansas - Chanute
-
Dodge City, Kansas, Vereinigte Staaten, 67801
- Cancer Center of Kansas - Dodge City
-
El Dorado, Kansas, Vereinigte Staaten, 67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott, Kansas, Vereinigte Staaten, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Vereinigte Staaten, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, Vereinigte Staaten, 67068
- Cancer Center of Kansas-Kingman
-
Lawrence, Kansas, Vereinigte Staaten, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Vereinigte Staaten, 67905
- Cancer Center of Kansas-Liberal
-
Newton, Kansas, Vereinigte Staaten, 67114
- Cancer Center of Kansas - Newton
-
Parsons, Kansas, Vereinigte Staaten, 67357
- Cancer Center of Kansas - Parsons
-
Pratt, Kansas, Vereinigte Staaten, 67124
- Cancer Center of Kansas - Pratt
-
Salina, Kansas, Vereinigte Staaten, 67401
- Cancer Center of Kansas - Salina
-
Wellington, Kansas, Vereinigte Staaten, 67152
- Cancer Center of Kansas - Wellington
-
Wichita, Kansas, Vereinigte Staaten, 67214
- Ascension Via Christi Hospitals Wichita
-
Wichita, Kansas, Vereinigte Staaten, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Vereinigte Staaten, 67214
- Cancer Center of Kansas - Wichita
-
Wichita, Kansas, Vereinigte Staaten, 67208
- Associates In Womens Health
-
Winfield, Kansas, Vereinigte Staaten, 67156
- Cancer Center of Kansas - Winfield
-
-
Kentucky
-
Bardstown, Kentucky, Vereinigte Staaten, 40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Corbin, Kentucky, Vereinigte Staaten, 40701
- Commonwealth Cancer Center-Corbin
-
Lexington, Kentucky, Vereinigte Staaten, 40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington, Kentucky, Vereinigte Staaten, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Jewish Hospital
-
Louisville, Kentucky, Vereinigte Staaten, 40245
- UofL Health Medical Center Northeast
-
Louisville, Kentucky, Vereinigte Staaten, 40215
- Saints Mary and Elizabeth Hospital
-
Shepherdsville, Kentucky, Vereinigte Staaten, 40165
- Jewish Hospital Medical Center South
-
-
Maine
-
Scarborough, Maine, Vereinigte Staaten, 04074
- MaineHealth Maine Medical Center- Scarborough
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital Cancer Center
-
Burlington, Massachusetts, Vereinigte Staaten, 01805
- Lahey Clinic
-
-
Michigan
-
Brownstown, Michigan, Vereinigte Staaten, 48183
- Henry Ford Cancer Institute-Downriver
-
Clinton Township, Michigan, Vereinigte Staaten, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, Vereinigte Staaten, 48126
- Henry Ford Medical Center-Fairlane
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Vereinigte Staaten, 48334
- Weisberg Cancer Treatment Center
-
Novi, Michigan, Vereinigte Staaten, 48377
- Henry Ford Medical Center-Columbus
-
West Bloomfield, Michigan, Vereinigte Staaten, 48322
- Henry Ford West Bloomfield Hospital
-
-
Missouri
-
Bolivar, Missouri, Vereinigte Staaten, 65613
- Central Care Cancer Center - Bolivar
-
Bonne Terre, Missouri, Vereinigte Staaten, 63628
- Parkland Health Center-Bonne Terre
-
Branson, Missouri, Vereinigte Staaten, 65616
- Cox Cancer Center Branson
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63703
- Mercy Cancer Center - Cape Girardeau
-
Jefferson City, Missouri, Vereinigte Staaten, 65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Vereinigte Staaten, 64804
- Freeman Health System
-
Joplin, Missouri, Vereinigte Staaten, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, Vereinigte Staaten, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Vereinigte Staaten, 65401
- Phelps Health Delbert Day Cancer Institute
-
Sainte Genevieve, Missouri, Vereinigte Staaten, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Vereinigte Staaten, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Vereinigte Staaten, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Vereinigte Staaten, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Vereinigte Staaten, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Vereinigte Staaten, 63141
- Mercy Hospital Saint Louis
-
Sullivan, Missouri, Vereinigte Staaten, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Anaconda, Montana, Vereinigte Staaten, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Vereinigte Staaten, 59101
- Billings Clinic Cancer Center
-
Billings, Montana, Vereinigte Staaten, 59101
- Saint Vincent Healthcare
-
Bozeman, Montana, Vereinigte Staaten, 59715
- Bozeman Health Deaconess Hospital
-
Butte, Montana, Vereinigte Staaten, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Great Falls Clinic
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Vereinigte Staaten, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Vereinigte Staaten, 59901
- Logan Health Medical Center
-
Missoula, Montana, Vereinigte Staaten, 59802
- Saint Patrick Hospital - Community Hospital
-
Missoula, Montana, Vereinigte Staaten, 59804
- Community Medical Center
-
-
Nebraska
-
Grand Island, Nebraska, Vereinigte Staaten, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney, Nebraska, Vereinigte Staaten, 68847
- CHI Health Good Samaritan
-
Kearney, Nebraska, Vereinigte Staaten, 68845
- Fred and Pamela Buffett Cancer Center - Kearney
-
Lincoln, Nebraska, Vereinigte Staaten, 68510
- Saint Elizabeth Regional Medical Center
-
Omaha, Nebraska, Vereinigte Staaten, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Vereinigte Staaten, 68122
- Alegent Health Immanuel Medical Center
-
Omaha, Nebraska, Vereinigte Staaten, 68130
- Alegent Health Lakeside Hospital
-
Omaha, Nebraska, Vereinigte Staaten, 68122
- Hematology and Oncology Consultants PC
-
Papillion, Nebraska, Vereinigte Staaten, 68046
- Midlands Community Hospital
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89106
- Women's Cancer Center of Nevada
-
-
New Jersey
-
Camden, New Jersey, Vereinigte Staaten, 08103
- Cooper Hospital University Medical Center
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Hackensack University Medical Center
-
Voorhees Township, New Jersey, Vereinigte Staaten, 08043
- MD Anderson Cancer Center at Cooper-Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- University of New Mexico Cancer Center
-
-
New York
-
New York, New York, Vereinigte Staaten, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Clinton, North Carolina, Vereinigte Staaten, 28328
- Southeastern Medical Oncology Center-Clinton
-
Clinton, North Carolina, Vereinigte Staaten, 28328
- Sampson Radiation Oncology
-
Goldsboro, North Carolina, Vereinigte Staaten, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Goldsboro, North Carolina, Vereinigte Staaten, 27534
- Wayne Memorial Hospital
-
Goldsboro, North Carolina, Vereinigte Staaten, 27534
- Wayne Radiation Oncology
-
Jacksonville, North Carolina, Vereinigte Staaten, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Jacksonville, North Carolina, Vereinigte Staaten, 28546
- Onslow Memorial Hospital
-
-
Ohio
-
Beachwood, Ohio, Vereinigte Staaten, 44122
- UHHS-Chagrin Highlands Medical Center
-
Belpre, Ohio, Vereinigte Staaten, 45714
- Strecker Cancer Center-Belpre
-
Centerville, Ohio, Vereinigte Staaten, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Vereinigte Staaten, 45459
- Dayton Physicians LLC-Miami Valley South
-
Chillicothe, Ohio, Vereinigte Staaten, 45601
- Adena Regional Medical Center
-
Cincinnati, Ohio, Vereinigte Staaten, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Vereinigte Staaten, 45242
- Bethesda North Hospital
-
Cincinnati, Ohio, Vereinigte Staaten, 45236
- Oncology Hematology Care Inc-Kenwood
-
Cincinnati, Ohio, Vereinigte Staaten, 45247
- TriHealth Cancer Institute-Westside
-
Cincinnati, Ohio, Vereinigte Staaten, 45255
- TriHealth Cancer Institute-Anderson
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Vereinigte Staaten, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Vereinigte Staaten, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Vereinigte Staaten, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Vereinigte Staaten, 43228
- Doctors Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43213
- Mount Carmel East Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43215
- Grant Medical Center
-
Columbus, Ohio, Vereinigte Staaten, 43222
- Mount Carmel Health Center West
-
Dayton, Ohio, Vereinigte Staaten, 45406
- Good Samaritan Hospital - Dayton
-
Dayton, Ohio, Vereinigte Staaten, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Vereinigte Staaten, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Vereinigte Staaten, 45415
- Dayton Physician LLC - Englewood
-
Delaware, Ohio, Vereinigte Staaten, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Vereinigte Staaten, 43015
- Delaware Radiation Oncology
-
Delaware, Ohio, Vereinigte Staaten, 43015
- Grady Memorial Hospital
-
Findlay, Ohio, Vereinigte Staaten, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, Vereinigte Staaten, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, Vereinigte Staaten, 45840
- Orion Cancer Care
-
Franklin, Ohio, Vereinigte Staaten, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, Vereinigte Staaten, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Vereinigte Staaten, 45331
- Wayne Hospital
-
Greenville, Ohio, Vereinigte Staaten, 45331
- Dayton Physicians LLC-Wayne
-
Kettering, Ohio, Vereinigte Staaten, 45429
- Kettering Medical Center
-
Kettering, Ohio, Vereinigte Staaten, 45409
- Greater Dayton Cancer Center
-
Lancaster, Ohio, Vereinigte Staaten, 43130
- Fairfield Medical Center
-
Marietta, Ohio, Vereinigte Staaten, 45750
- Marietta Memorial Hospital
-
Marion, Ohio, Vereinigte Staaten, 43302
- OhioHealth Marion General Hospital
-
Mayfield Heights, Ohio, Vereinigte Staaten, 44124
- Hillcrest Hospital Cancer Center
-
Mayfield Heights, Ohio, Vereinigte Staaten, 44124
- UH Seidman Cancer Center at Landerbrook Health Center
-
Mentor, Ohio, Vereinigte Staaten, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Middletown, Ohio, Vereinigte Staaten, 45042
- Dayton Physicians LLC-Signal Point
-
Mount Vernon, Ohio, Vereinigte Staaten, 43050
- Knox Community Hospital
-
Newark, Ohio, Vereinigte Staaten, 43055
- Licking Memorial Hospital
-
Newark, Ohio, Vereinigte Staaten, 43055
- Newark Radiation Oncology
-
Portsmouth, Ohio, Vereinigte Staaten, 45662
- Southern Ohio Medical Center
-
Sidney, Ohio, Vereinigte Staaten, 45365
- Dayton Physicians LLC-Wilson
-
Springfield, Ohio, Vereinigte Staaten, 45504
- Springfield Regional Cancer Center
-
Springfield, Ohio, Vereinigte Staaten, 45504
- Springfield Regional Medical Center
-
Troy, Ohio, Vereinigte Staaten, 45373
- Upper Valley Medical Center
-
Troy, Ohio, Vereinigte Staaten, 45373
- Dayton Physicians LLC - Troy
-
Wadsworth, Ohio, Vereinigte Staaten, 44281
- University Hospitals Sharon Health Center
-
Westerville, Ohio, Vereinigte Staaten, 43081
- Saint Ann's Hospital
-
Westlake, Ohio, Vereinigte Staaten, 44145
- UHHS-Westlake Medical Center
-
Zanesville, Ohio, Vereinigte Staaten, 43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Vereinigte Staaten, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Bend, Oregon, Vereinigte Staaten, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Vereinigte Staaten, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Vereinigte Staaten, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Vereinigte Staaten, 97420
- Bay Area Hospital
-
Newberg, Oregon, Vereinigte Staaten, 97132
- Providence Newberg Medical Center
-
Oregon City, Oregon, Vereinigte Staaten, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Vereinigte Staaten, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Vereinigte Staaten, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Abington, Pennsylvania, Vereinigte Staaten, 19001
- Jefferson Abington Hospital
-
Allentown, Pennsylvania, Vereinigte Staaten, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Vereinigte Staaten, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Chadds Ford, Pennsylvania, Vereinigte Staaten, 19317
- Christiana Care Health System-Concord Health Center
-
Ephrata, Pennsylvania, Vereinigte Staaten, 17522
- Ephrata Cancer Center
-
Gettysburg, Pennsylvania, Vereinigte Staaten, 17325
- Adams Cancer Center
-
Hanover, Pennsylvania, Vereinigte Staaten, 17331
- WellSpan Medical Oncology and Hematology
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- University of Pennsylvania/Abramson Cancer Center
-
West Reading, Pennsylvania, Vereinigte Staaten, 19611
- Reading Hospital
-
York, Pennsylvania, Vereinigte Staaten, 17403
- WellSpan Health-York Cancer Center
-
York, Pennsylvania, Vereinigte Staaten, 17403
- WellSpan Health-York Hospital
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02905
- Women and Infants Hospital
-
-
South Carolina
-
Boiling Springs, South Carolina, Vereinigte Staaten, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Medical University of South Carolina
-
Easley, South Carolina, Vereinigte Staaten, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Vereinigte Staaten, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Vereinigte Staaten, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Vereinigte Staaten, 29601
- Saint Francis Hospital
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Prisma Health Greenville Memorial Hospital
-
Greenville, South Carolina, Vereinigte Staaten, 29601
- Greenville Health System Cancer Institute-Andrews
-
Greer, South Carolina, Vereinigte Staaten, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Vereinigte Staaten, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57105
- Avera Cancer Institute
-
-
Tennessee
-
Chattanooga, Tennessee, Vereinigte Staaten, 37404
- Memorial Hospital
-
Hixson, Tennessee, Vereinigte Staaten, 37343
- Pulmonary Medicine Center of Chattanooga-Hixson
-
Ooltewah, Tennessee, Vereinigte Staaten, 37363
- Memorial GYN Plus
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- UT MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Huntsman Cancer Institute/University of Utah
-
South Jordan, Utah, Vereinigte Staaten, 84009
- South Jordan Health Center
-
-
Virginia
-
Falls Church, Virginia, Vereinigte Staaten, 22042
- Inova Fairfax Hospital
-
-
Washington
-
Aberdeen, Washington, Vereinigte Staaten, 98520
- Providence Regional Cancer System-Aberdeen
-
Anacortes, Washington, Vereinigte Staaten, 98221
- Cancer Care Center at Island Hospital
-
Bellevue, Washington, Vereinigte Staaten, 98005
- Swedish Cancer Institute-Eastside Oncology Hematology
-
Bellingham, Washington, Vereinigte Staaten, 98225
- PeaceHealth Saint Joseph Medical Center
-
Burien, Washington, Vereinigte Staaten, 98166
- Saint Anne Hospital
-
Centralia, Washington, Vereinigte Staaten, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Vereinigte Staaten, 98026
- Swedish Cancer Institute-Edmonds
-
Enumclaw, Washington, Vereinigte Staaten, 98022
- Saint Elizabeth Hospital
-
Everett, Washington, Vereinigte Staaten, 98201
- Providence Regional Cancer Partnership
-
Federal Way, Washington, Vereinigte Staaten, 98003
- Saint Francis Hospital
-
Issaquah, Washington, Vereinigte Staaten, 98029
- Swedish Cancer Institute-Issaquah
-
Lacey, Washington, Vereinigte Staaten, 98503
- Providence Regional Cancer System-Lacey
-
Lakewood, Washington, Vereinigte Staaten, 98499
- Saint Clare Hospital
-
Longview, Washington, Vereinigte Staaten, 98632
- PeaceHealth Saint John Medical Center
-
Poulsbo, Washington, Vereinigte Staaten, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Seattle, Washington, Vereinigte Staaten, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Vereinigte Staaten, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Vereinigte Staaten, 98195
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Vereinigte Staaten, 98112
- Kaiser Permanente Washington
-
Seattle, Washington, Vereinigte Staaten, 98104
- Minor and James Medical PLLC
-
Seattle, Washington, Vereinigte Staaten, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Vereinigte Staaten, 98109
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Vereinigte Staaten, 98133
- University of Washington Medical Center - Northwest
-
Seattle, Washington, Vereinigte Staaten, 98133
- Women's Cancer Center of Seattle
-
Shelton, Washington, Vereinigte Staaten, 98584
- Providence Regional Cancer System-Shelton
-
Silverdale, Washington, Vereinigte Staaten, 98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Spokane, Washington, Vereinigte Staaten, 99218
- Evergreen Hematology and Oncology PS
-
Spokane, Washington, Vereinigte Staaten, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane Valley, Washington, Vereinigte Staaten, 99216
- MultiCare Deaconess Cancer and Blood Specialty Center - Valley
-
Tacoma, Washington, Vereinigte Staaten, 98405
- Northwest Medical Specialties PLLC
-
Tacoma, Washington, Vereinigte Staaten, 98405
- Franciscan Research Center-Northwest Medical Plaza
-
Vancouver, Washington, Vereinigte Staaten, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Vereinigte Staaten, 99362
- Providence Saint Mary Regional Cancer Center
-
Yakima, Washington, Vereinigte Staaten, 98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
Yelm, Washington, Vereinigte Staaten, 98597
- Providence Regional Cancer System-Yelm
-
-
West Virginia
-
Morgantown, West Virginia, Vereinigte Staaten, 26505
- Monongalia Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Medical College of Wisconsin
-
-
Wyoming
-
Cody, Wyoming, Vereinigte Staaten, 82414
- Big Horn Basin Cancer Center
-
Cody, Wyoming, Vereinigte Staaten, 82414
- Billings Clinic-Cody
-
Sheridan, Wyoming, Vereinigte Staaten, 82801
- Welch Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Patients must have persistent, recurrent or metastatic squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix with documented disease progression (disease not amendable to curative therapy); NOTE: the following cervical tumors are not eligible: minimal deviation/adenoma malignum, gastric type adenocarcinoma, clear cell carcinoma and mesonephric carcinoma; histologic confirmation of the original primary tumor is required via the pathology report
-
All patents must have measurable disease as defined by RECIST 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
-
Patients must have at least one "target" lesion" to be used to assess response on this protocol as defined by RECIST 1.1; tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
-
Appropriate for study entry based on the following diagnostic workup:
-
History/physical examination within 28 days prior to registration
-
Imaging of target lesion(s) within 28 days prior to registration
-
Further protocol-specific assessments:
- Recovery from adverse effects of recent surgery, radiotherapy or chemotherapy
- Any other prior therapy directed at the malignant tumor including chemotherapy, biologic/targeted agents and immunologic agents must be discontinued at least three weeks prior to registration
- Investigation agents must be discontinued for at least 30 days prior to registration
- Any prior radiation therapy must be completed at least 4 weeks prior to registration
- At least 4 weeks must have elapsed since any major surgery prior to registration
-
-
Patients must have had one prior systemic chemotherapeutic regimen for management of persistent, recurrent or metastatic carcinoma of the cervix (e.g.; paclitaxel/cisplatin, paclitaxel/cisplatin/bevacizumab); chemotherapy administered concurrent with primary radiation (e.g.; weekly cisplatin) is not counted as a systemic chemotherapy regimen; adjuvant chemotherapy given following the completion of radiation therapy (or concurrent chemotherapy and radiation therapy) is not counted as a systemic chemotherapy regimen (e.g.; paclitaxel and carboplatin for up to 4 cycles); NOTE: patients who have received more than one prior regimen are NOT eligible
-
Performance status of 0 or 1
-
Absolute neutrophil count (ANC) >= 1,500/ul
-
Platelets >= 100,000/ul
-
Creatinine =< 1.5 x institutional upper limit of normal (ULN) or creatinine clearance (CrCl) >= 40 mL/min using Cockcroft-Gault formula
-
Bilirubin =< 1.5 x ULN
-
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
-
Normal thyroid function testing (thyroid stimulating hormone [TSH]) within 14 days prior to registration
-
The patient or a legally authorized representative must provide study-specific informed consent authorization permitting release of personal health information prior to study entry
Exclusion Criteria:
-
Patients who have had prior therapy with nivolumab or with an anti-PD-1, anti-PD-ligand (L)1, anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune check point pathways
-
History of severe hypersensitivity reaction to any monoclonal antibody
-
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
-
Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure and unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Patients who are pregnant or nursing; women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 23 weeks after the last dose of investigational drug; WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IV/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab; women must not be breastfeeding
- Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile or have undergone definitive radiation) do not require contraception
- Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy of bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 month amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level greater than 40 mIU/mL
- WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product
- Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform the treating physician immediately
-
Patients with known brain metastases or leptomeningeal metastases are excluded unless the following conditions are met:
- Metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for at least 4 weeks after treatment is complete (must be confirmed within 28 days prior to the first dose of nivolumab administration)
- There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration
-
Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- Patients should be excluded if they have a positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded; these include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IRB), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded; patient with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible; patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
- NOTE: patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)
-
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
-
Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, abdominal/pelvic fistula, gastrointestinal perforation, gastrointestinal (GI) obstruction and/or who require parenteral hydration and/or nutrition
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Treatment (nivolumab)
Patients receive nivolumab IV over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity. |
Correlative studies Given IV
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective Tumor Response as Assessed by RECIST 1.1 Criteria
Zeitfenster: The average of study treatment time was 3.8 months.
|
Proportion of participants with objective tumor response. Objective tumor response is defined as complete or partial tumor response assessed by RECIST 1.1. |
The average of study treatment time was 3.8 months.
|
|
Adverse Events (Grade 3 or Higher) During Treatment Period as Assessed by CTCAE Version 4
Zeitfenster: Within 100 days of last protocol treatment
|
Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v4.0. |
Within 100 days of last protocol treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-free Survival
Zeitfenster: Time from study entry to time of progression or death, whichever occurs first, up to 5 years of follow-up.
|
Progression-free survival is the period of time from study entry to time of disease progression, death or date of last contact, whichever occurs first. Progression is assessed by RECIST 1.1. |
Time from study entry to time of progression or death, whichever occurs first, up to 5 years of follow-up.
|
|
Overall Survival
Zeitfenster: Time from study entry to time of death or the date of last contact, up to 5 years of follow-up
|
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. |
Time from study entry to time of death or the date of last contact, up to 5 years of follow-up
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Tumor Expressions of PD-1 and PD-L1 in Tumor Infiltrating Lymphocytes and Cervical Cancer Cells
Zeitfenster: Up to 5 years
|
Spearman's correlation coefficient will be used to explore the associations of tumor expressions of PD-L1, PD-1 and other interested biomarkers with tumor response. Cox proportional hazards (PH) model will be utilized to evaluate the associations of these tumor expressions with PFS and OS. These expressions may also be dichotomized into high versus low values (cut at the median). Log-rank tests will be used to assess the associations of these dichotomized tumor expressions with PFS and OS. The corresponding hazard rations will be estimated by Cox PH models. |
Up to 5 years
|
|
Immune Infiltration Related Biomarkers (i.e., CD4+, CD8+, FoxP3) in Tumor Specimens
Zeitfenster: Up to 5 years
|
Immune infiltration related biomarkers (i.e., CD4+, CD8+, FoxP3) in tumor specimens will be associated with objective tumor response, PFS and OS in nivolumab-treated patients. |
Up to 5 years
|
|
Change in the Immune Response to HPV 16/18/31/35/45 E7 Antigen in Peripheral Blood Lymphocytes and Serum
Zeitfenster: Baseline to up to 5 years
|
Wilcoxon signed rank test (for interval or ordinal data) or McNemar's test (for binary data) may be utilized to examine whether the study treatment will change immune response to HPV 16/18/31/35/45 E7 antigen in peripheral blood lymphocytes and serum by changes in the measures of pre- and post-treatment immune response to HPV 16/18/31/35/45 E7. |
Baseline to up to 5 years
|
|
Change in the CTC Count
Zeitfenster: Baseline to up to 12 weeks
|
Change in the CTC count and whether the CTC count is associated with objective response, PFS and OS in nivolumab-treated patients will be evaluated. |
Baseline to up to 12 weeks
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Alessandro D Santin, NRG Oncology
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Uteruserkrankungen
- Genitalerkrankungen, weiblich
- Genitale Neubildungen, weiblich
- Gebärmutterhalskrankheiten
- Uterusneoplasmen
- Gebärmutterhalstumoren
- Aminosäuren, Peptide und Proteine
- Proteine
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Nivolumab
Andere Studien-ID-Nummern
- NCI-2014-02021
- U10CA180868 (US NIH Stipendium/Vertrag)
- NCI-2014-02021 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- PNRG-GY002_A01PAMDREVW01
- NRG-GY002 (Andere Kennung: CTEP)
- NRG-GY002
- NRG-GY002 (Andere Kennung: NRG Oncology)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .